+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Marine Pharmaceuticals Market 2024-2028

  • PDF Icon

    Report

  • 176 Pages
  • November 2023
  • Region: Global
  • TechNavio
  • ID: 5300882
1h Free Analyst Time

The market is driven by licensing agreements, the growing prevalence of chronic diseases, and the vast availability of raw materials

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The marine pharmaceuticals market is forecasted to grow by USD 1.95 billion during 2023-2028, accelerating at a CAGR of 8.63% during the forecast period. The report on the marine pharmaceuticals market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising consumer demand for natural products, the growing prevalence of chronic diseases, and the presence of rich marine biodiversity.

The marine pharmaceuticals market is segmented as below:

By Product

  • Oncology
  • Cardiovascular
  • Anti-infectives
  • Others

By Type

  • Health supplements
  • Drugs

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the rise of antibiotics from marine microbes as one of the prime reasons driving the marine pharmaceuticals market growth during the next few years. Also, research for anti-inflammatory compounds from marine sources and the emergence of digitalization and data analytics will lead to sizable demand in the market.

The report on the marine pharmaceuticals market covers the following areas:

  • Marine pharmaceuticals market sizing
  • Marine pharmaceuticals market forecast
  • Marine pharmaceuticals market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading marine pharmaceuticals market vendors that include Abbott Laboratories, BASF SE, BeyondSpring Inc., BioMarin Pharmaceutical Inc., Bristol Myers Squibb Co., Croda International Plc, DEKRA SE, EID Parry India Ltd., Eisai Co. Ltd., GFR Pharma, GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Koninklijke DSM NV, MARINE LIFESCIENCES, Merck KGaA, Pfizer Inc., PharmaMar SA, Roquette Freres SA, TerSera Therapeutics LLC, and ZELNOVA ZELTIA S.A.. Also, the marine pharmaceuticals market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market Overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size
4.1 Global cancer immunotherapy market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global cancer immunotherapy market 2017 - 2021 ($ million)
4.2 Type Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ million)
4.3 Application Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Application Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product
6.1 Market segments
Exhibit 30: Chart on Product - Market share 2023-2028 (%)
Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Oncology - Market size and forecast 2023-2028
Exhibit 34: Chart on Oncology - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Oncology - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Oncology - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Oncology - Year-over-year growth 2023-2028 (%)
6.4 Cardiovascular - Market size and forecast 2023-2028
Exhibit 38: Chart on Cardiovascular - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Cardiovascular - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Cardiovascular - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Cardiovascular - Year-over-year growth 2023-2028 (%)
6.5 Anti-infectives - Market size and forecast 2023-2028
Exhibit 42: Chart on Anti-infectives - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Anti-infectives - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Anti-infectives - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Anti-infectives - Year-over-year growth 2023-2028 (%)
6.6 Others - Market size and forecast 2023-2028
Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.7 Market opportunity by Product
Exhibit 50: Market opportunity by Product ($ million)
Exhibit 51: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Type
7.1 Market segments
Exhibit 52: Chart on Type - Market share 2023-2028 (%)
Exhibit 53: Data Table on Type - Market share 2023-2028 (%)
7.2 Comparison by Type
Exhibit 54: Chart on Comparison by Type
Exhibit 55: Data Table on Comparison by Type
7.3 Health supplements - Market size and forecast 2023-2028
Exhibit 56: Chart on Health supplements - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Health supplements - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Health supplements - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Health supplements - Year-over-year growth 2023-2028 (%)
7.4 Drugs - Market size and forecast 2023-2028
Exhibit 60: Chart on Drugs - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Drugs - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Drugs - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Drugs - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Type
Exhibit 64: Market opportunity by Type ($ million)
Exhibit 65: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape
8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 67: Chart on Market share by geography 2023-2028 (%)
Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 China - Market size and forecast 2023-2028
Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
9.10 Canada - Market size and forecast 2023-2028
Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.11 UK - Market size and forecast 2023-2028
Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity by geography
Exhibit 107: Market opportunity by geography ($ million)
Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis
12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 BASF SE
Exhibit 115: BASF SE - Overview
Exhibit 116: BASF SE - Business segments
Exhibit 117: BASF SE - Key news
Exhibit 118: BASF SE - Key offerings
Exhibit 119: BASF SE - Segment focus
12.4 BeyondSpring Inc.
Exhibit 120: BeyondSpring Inc. - Overview
Exhibit 121: BeyondSpring Inc. - Product / Service
Exhibit 122: BeyondSpring Inc. - Key offerings
12.5 BioMarin Pharmaceutical Inc.
Exhibit 123: BioMarin Pharmaceutical Inc. - Overview
Exhibit 124: BioMarin Pharmaceutical Inc. - Product / Service
Exhibit 125: BioMarin Pharmaceutical Inc. - Key offerings
12.6 Bristol Myers Squibb Co.
Exhibit 126: Bristol Myers Squibb Co. - Overview
Exhibit 127: Bristol Myers Squibb Co. - Product / Service
Exhibit 128: Bristol Myers Squibb Co. - Key news
Exhibit 129: Bristol Myers Squibb Co. - Key offerings
12.7 Croda International Plc
Exhibit 130: Croda International Plc - Overview
Exhibit 131: Croda International Plc - Business segments
Exhibit 132: Croda International Plc - Key news
Exhibit 133: Croda International Plc - Key offerings
Exhibit 134: Croda International Plc - Segment focus
12.8 Eisai Co. Ltd.
Exhibit 135: Eisai Co. Ltd. - Overview
Exhibit 136: Eisai Co. Ltd. - Business segments
Exhibit 137: Eisai Co. Ltd. - Key offerings
Exhibit 138: Eisai Co. Ltd. - Segment focus
12.9 GFR Pharma
Exhibit 139: GFR Pharma - Overview
Exhibit 140: GFR Pharma - Product / Service
Exhibit 141: GFR Pharma - Key offerings
12.10 GlaxoSmithKline Plc
Exhibit 142: GlaxoSmithKline Plc - Overview
Exhibit 143: GlaxoSmithKline Plc - Business segments
Exhibit 144: GlaxoSmithKline Plc - Key news
Exhibit 145: GlaxoSmithKline Plc - Key offerings
Exhibit 146: GlaxoSmithKline Plc - Segment focus
12.11 Jazz Pharmaceuticals Plc
Exhibit 147: Jazz Pharmaceuticals Plc - Overview
Exhibit 148: Jazz Pharmaceuticals Plc - Product / Service
Exhibit 149: Jazz Pharmaceuticals Plc - Key news
Exhibit 150: Jazz Pharmaceuticals Plc - Key offerings
12.12 Koninklijke DSM NV
Exhibit 151: Koninklijke DSM NV - Overview
Exhibit 152: Koninklijke DSM NV - Business segments
Exhibit 153: Koninklijke DSM NV - Key news
Exhibit 154: Koninklijke DSM NV - Key offerings
Exhibit 155: Koninklijke DSM NV - Segment focus
12.13 Merck KGaA
Exhibit 156: Merck KGaA - Overview
Exhibit 157: Merck KGaA - Business segments
Exhibit 158: Merck KGaA - Key news
Exhibit 159: Merck KGaA - Key offerings
Exhibit 160: Merck KGaA - Segment focus
12.14 Pfizer Inc.
Exhibit 161: Pfizer Inc. - Overview
Exhibit 162: Pfizer Inc. - Product / Service
Exhibit 163: Pfizer Inc. - Key news
Exhibit 164: Pfizer Inc. - Key offerings
12.15 PharmaMar SA
Exhibit 165: PharmaMar SA - Overview
Exhibit 166: PharmaMar SA - Business segments
Exhibit 167: PharmaMar SA - Key offerings
Exhibit 168: PharmaMar SA - Segment focus
12.16 TerSera Therapeutics LLC
Exhibit 169: TerSera Therapeutics LLC - Overview
Exhibit 170: TerSera Therapeutics LLC - Product / Service
Exhibit 171: TerSera Therapeutics LLC - Key offerings
12.17 ZELNOVA ZELTIA S.A.
Exhibit 172: ZELNOVA ZELTIA S.A. - Overview
Exhibit 173: ZELNOVA ZELTIA S.A. - Product / Service
Exhibit 174: ZELNOVA ZELTIA S.A. - Key offerings

13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 175: Inclusions checklist
Exhibit 176: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 177: Currency conversion rates for US$
13.4 Research methodology
Exhibit 178: Research methodology
Exhibit 179: Validation techniques employed for market sizing
Exhibit 180: Information sources
13.5 List of abbreviations
Exhibit 181: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global marine pharmaceuticals market: Abbott Laboratories, BASF SE, BeyondSpring Inc., BioMarin Pharmaceutical Inc., Bristol Myers Squibb Co., Croda International Plc, DEKRA SE, EID Parry India Ltd., Eisai Co. Ltd., GFR Pharma, GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Koninklijke DSM NV, MARINE LIFESCIENCES, Merck KGaA, Pfizer Inc., PharmaMar SA, Roquette Freres SA, TerSera Therapeutics LLC, and ZELNOVA ZELTIA S.A..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the rise of antibiotics from marine microbes.'

According to the report, one of the major drivers for this market is the rising consumer demand for natural products.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • BASF SE
  • BeyondSpring Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb Co.
  • Croda International Plc
  • DEKRA SE
  • EID Parry India Ltd.
  • Eisai Co. Ltd.
  • GFR Pharma
  • GlaxoSmithKline Plc
  • Jazz Pharmaceuticals Plc
  • Koninklijke DSM NV
  • MARINE LIFESCIENCES
  • Merck KGaA
  • Pfizer Inc.
  • PharmaMar SA
  • Roquette Freres SA
  • TerSera Therapeutics LLC
  • ZELNOVA ZELTIA S.A.